Description
A prodrug of uridine; decreases neurodegeneration in the piriform cortex and striatum, as well as reduces the amount of huntingtin-positive aggregates and increases BDNF protein levels in the piriform cortex in a transgenic mouse model of Huntington’s disease at 6% in the diet; improves rotarod performance and increases survival in transgenic mouse models of Huntington’s disease; reverses toxicity and increases survival in a mouse model of DPD deficiency-induced 5-FU overdose at 2,000 mg/kg three times per day beginning within 24 hours of 5-FU administration
Formal name: 2′,3′,5′-triacetate uridine
Synonyms: 2′,3′,5′-Tri-O-acetyluridine|PN401|RG2133|Uridine Triacetate
Molecular weight: 370.3
CAS: 4105-38-8
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Nucleotides/Nucleosides||Research Area|Cancer|DNA Damage and Repair||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Neuroscience|Neurodegenerative Disorders|Huntington’s Disease||Research Area|Neuroscience|Neuroprotection||Research Area|Toxicology
